+34 9340006100 -ext. 437807-info@nanbiosis.com

Posts Taged niosomes

Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference

Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference.

On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in the city brings together professionals from the health system of Alava, the Rioja region of Alava, the Mental Health Network of Alava, the University of the Basque Country and also professionals from companies in R&D&I in health.

On this occasion, the NanoBioCel research group of the CIBER BBN and the ICTS Nanbiosis through the U10 Drug Formulation, won the 3 prizes in the category of Research and Innovation in the category of Best International Article. The first prize went to the article: Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation. Written by Ainhoa Gonzalez-Pujana, Ana Beloqui, José Javier Aguirre, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez, published in the European Journal of Pharmaceutics and Biopharmaceutics in 2022. The second prize went to the article Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases whose authors are: Nuseibah AL Qtaish, Idoia Gallego, Alejandro J. Paredes,Ilia Villate, Cristina Soto-Sánchez, Gema Martínez, Myriam Sainz-Ramos, Tania B. López, Eduardo Fernández, Gustavo Puras, José Luis Pedraz. And the third prize went to the review: Cell microencapsulation technologies for sustained drug delivery: Latest advancesin efficacy and biosafety whose authors are: Tania B. López, Edorta Santos, José Luis Pedraz, Gorka Orive, Rosa María Hernández.

Articles of refernce:

Ainhoa Gonzalez-Pujana, Ana Beloqui, José Javier Aguirre, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez, “Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation“, European Journal of Pharmaceutics and Biopharmaceutics, Volume 172,
2022, https://doi.org/10.1016/j.ejpb.2022.01.007

Nuseibah AL Qtaish, Idoia Gallego, Alejandro J. Paredes, Ilia Villate-Beitia, Cristina Soto-Sánchez, Gema Martínez-Navarrete, Myriam Sainz-Ramos, Tania B. Lopez-Mendez, Eduardo Fernández, Gustavo Puras, José Luis Pedraz. “Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System DiseasesACS Appl. Mater. Interfaces 2022, 14, 11, 13665–13677 https://doi.org/10.1021/acsami.2c02182

Tania B. Lopez-Mendez, Edorta Santos-Vizcaino, Jose Luis Pedraz, Gorka Orive, Rosa Maria Hernandez, “Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety,
Journal of Controlled Release”,
Journal of Controlled Release, Volume 335, 10 July 2021, Pages 619-636 https://doi.org/10.1016/j.jconrel.2021.06.006


Read More

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

Researchers of CIBER-BBN Units of NANBIOSIS: U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Prof. Ramón Eritja and U10 Drug Formulation, at UPV-EHU, led by Prof José Luis Pedraz, are coauthors of an article published by International Journal of Pharmaceutics.

Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option for the treatment of cystic fibrosis (CF), being liposomes the most commonly used gene carriers. Niosomes offer a powerful alternative to liposomes due to their higher stability and lower cytotoxicity, provided by their non-ionic surfactant and helper components. In this work, a three-formulation screening is performed, in terms of physicochemical and biological behavior, in CF patient derived airway epithelial cells. The most efficient niosome formulation reaches 28% of EGFP expressing live cells and follows caveolae-mediated endocytosis. Transfection with therapeutic cystic fibrosis transmembrane conductance regulator (CFTR) gene results in 5-fold increase of CFTR protein expression in transfected versus non-transfected cells, which leads to 1.5-fold increment of the chloride channel functionality. These findings highlight the relevance of niosome-based systems as an encouraging non-viral gene therapy platform with potential therapeutic benefits for CF.

The article acknowledges U10 Drug Formulation, for the intellectual and technical assistance

Article or reference:

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality-Sainz-Ramos, M., Villate-Beitia, I., Gallego, I., A.L. Qtaish, N., Lopez-Mendez, T.B., Eritja, R., Grijalvo, S., Puras, G., Pedraz, J.L. International Journal of Pharmaceutics, 588, art. no. 119757, 2020. https://doi.org/10.1016/j.ijpharm.2020.119757

Read More